| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chenjie Xia, Sara J Makaretz, Christina Caso, Scott McGinnis, Stephen N Gomperts, Jorge Sepulcre, Teresa Gomez-Isla, Bradley T Hyman, Aaron Schultz, Neil Vasdev, Keith A Johnson, Bradford C Dickerso. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA neurology. vol 74. issue 4. 2017-05-30. PMID:28241163. |
previous postmortem studies have long demonstrated that neurofibrillary tangles made of hyperphosphorylated tau proteins are closely associated with alzheimer disease clinical phenotype and neurodegeneration pattern. |
2017-05-30 |
2023-08-13 |
Not clear |
| Jesús Avila, Noemí Pallas, Marta Bolós, C Laura Sayas, Felix Hernande. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies. Expert opinion on therapeutic targets. vol 20. issue 6. 2017-05-29. PMID:26652296. |
intracellular and extracellular microtubule associated protein tau as a therapeutic target in alzheimer disease and other tauopathies. |
2017-05-29 |
2023-08-13 |
Not clear |
| Abbas M Walji, Eric D Hostetler, Harold Selnick, Zhizhen Zeng, Patricia Miller, Idriss Bennacef, Cristian Salinas, Brett Connolly, Liza Gantert, Marie Holahan, Stacey O'Malley, Mona Purcell, Kerry Riffel, Jing Li, Jaume Balsells, Julie A OBrien, Stacey Melquist, Aileen Soriano, Xiaoping Zhang, Aimie Ogawa, Serena Xu, Elizabeth Joshi, Joseph Della Rocca, Fred J Hess, Joel Schachter, David Hesk, David Schenk, Arie Struyk, Kerim Babaoglu, Talakad G Lohith, Yaode Wang, Kun Yang, Jianmin Fu, Jeffrey L Evelhoch, Paul J Colema. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). Journal of medicinal chemistry. vol 59. issue 10. 2017-05-29. PMID:27088900. |
neurofibrillary tangles (nfts) made up of aggregated tau protein have been identified as the pathologic hallmark of several neurodegenerative diseases including alzheimer's disease. |
2017-05-29 |
2023-08-13 |
Not clear |
| Kanae Ando, Mikiko Oka, Yosuke Ohtake, Motoki Hayashishita, Sawako Shimizu, Shin-Ichi Hisanaga, Koichi M Iijim. Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated. Biochemical and biophysical research communications. vol 478. issue 2. 2017-05-29. PMID:27520376. |
tau phosphorylation at alzheimer's disease-related ser356 contributes to tau stabilization when par-1/mark activity is elevated. |
2017-05-29 |
2023-08-13 |
human |
| Kanae Ando, Mikiko Oka, Yosuke Ohtake, Motoki Hayashishita, Sawako Shimizu, Shin-Ichi Hisanaga, Koichi M Iijim. Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated. Biochemical and biophysical research communications. vol 478. issue 2. 2017-05-29. PMID:27520376. |
abnormal phosphorylation of the microtubule-associated protein tau is observed in many neurodegenerative diseases, including alzheimer's disease (ad). |
2017-05-29 |
2023-08-13 |
human |
| Kun Ping Lu, Asami Kondo, Onder Albayram, Megan K Herbert, Hekun Liu, Xiao Zhen Zho. Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. JAMA neurology. vol 73. issue 11. 2017-05-29. PMID:27654282. |
potential of the antibody against cis-phosphorylated tau in the early diagnosis, treatment, and prevention of alzheimer disease and brain injury. |
2017-05-29 |
2023-08-13 |
mouse |
| Petr Novak, Reinhold Schmidt, Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Rostislav Skrabana, Zuzana Vince-Kazmerova, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek, Roman Sivak, Bengt Winblad, Michal Nova. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. Neurology. vol 16. issue 2. 2017-05-29. PMID:27955995. |
safety and immunogenicity of the tau vaccine aadvac1 in patients with alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. |
2017-05-29 |
2023-08-13 |
Not clear |
| Petr Novak, Reinhold Schmidt, Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Rostislav Skrabana, Zuzana Vince-Kazmerova, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek, Roman Sivak, Bengt Winblad, Michal Nova. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. Neurology. vol 16. issue 2. 2017-05-29. PMID:27955995. |
neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with alzheimer's disease. |
2017-05-29 |
2023-08-13 |
Not clear |
| Petr Novak, Reinhold Schmidt, Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Rostislav Skrabana, Zuzana Vince-Kazmerova, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek, Roman Sivak, Bengt Winblad, Michal Nova. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. Neurology. vol 16. issue 2. 2017-05-29. PMID:27955995. |
immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of alzheimer's disease. |
2017-05-29 |
2023-08-13 |
Not clear |
| Aoyan Dong, Jon B Toledo, Nicolas Honnorat, Jimit Doshi, Erdem Varol, Aristeidis Sotiras, David Wolk, John Q Trojanowski, Christos Davatziko. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28003242. |
amyloid and tau deposition) dimensions in alzheimer's disease and its prodromal stages. |
2017-05-29 |
2023-08-13 |
human |
| Michael J Pontecorvo, Michael D Devous, Michael Navitsky, Ming Lu, Stephen Salloway, Frederick W Schaerf, Danna Jennings, Anupa K Arora, Anne McGeehan, Nathaniel C Lim, Hui Xiong, Abhinay D Joshi, Andrew Siderowf, Mark A Mintu. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28077397. |
the advent of tau-targeted positron emission tomography tracers such as flortaucipir (18f-av-1451, also known as 18f-t807) have made it possible to investigate the sequence of development of tau and amyloid-β in relationship to age, and to the development of cognitive impairment due to alzheimer's disease. |
2017-05-29 |
2023-08-13 |
human |
| Michael J Pontecorvo, Michael D Devous, Michael Navitsky, Ming Lu, Stephen Salloway, Frederick W Schaerf, Danna Jennings, Anupa K Arora, Anne McGeehan, Nathaniel C Lim, Hui Xiong, Abhinay D Joshi, Andrew Siderowf, Mark A Mintu. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28077397. |
in this study, flortaucipir tau and florbetapir amyloid positron emission tomography were obtained for 217 subjects including 16 young and 58 older cognitively normal subjects, 95 subjects with mild cognitive impairment (mini-mental state examination 24-30) and 48 subjects with clinically-defined possible or probable alzheimer's disease (mini-mental state examination >10). |
2017-05-29 |
2023-08-13 |
human |
| Michael J Pontecorvo, Michael D Devous, Michael Navitsky, Ming Lu, Stephen Salloway, Frederick W Schaerf, Danna Jennings, Anupa K Arora, Anne McGeehan, Nathaniel C Lim, Hui Xiong, Abhinay D Joshi, Andrew Siderowf, Mark A Mintu. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28077397. |
finally, within the aβ+ group, increasing levels of flortaucipir tau binding were associated with increased cognitive impairment, as assessed by mini-mental state examination and alzheimer's disease assessment scale. |
2017-05-29 |
2023-08-13 |
human |
| Maiko Ono, Naruhiko Sahara, Katsushi Kumata, Bin Ji, Ruiqing Ni, Shunsuke Koga, Dennis W Dickson, John Q Trojanowski, Virginia M-Y Lee, Mari Yoshida, Isao Hozumi, Yasumasa Yoshiyama, John C van Swieten, Agneta Nordberg, Tetsuya Suhara, Ming-Rong Zhang, Makoto Higuch. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28087578. |
fluorescence microscopy demonstrated intense labelling of non-ghost and ghost tangles with pbb3 and av-1451, while dystrophic neurites were more clearly detected by pbb3 in brains of alzheimer's disease and diffuse neurofibrillary tangles with calcification, characterized by accumulation of all six tau isoforms. |
2017-05-29 |
2023-08-13 |
Not clear |
| Zhen Fan, David J Brooks, Aren Okello, Paul Ediso. An early and late peak in microglial activation in Alzheimer's disease trajectory. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122877. |
amyloid-β deposition, neuroinflammation and tau tangle formation all play a significant role in alzheimer's disease. |
2017-05-29 |
2023-08-13 |
human |
| Luca Passamonti, Patricia Vázquez Rodríguez, Young T Hong, Kieren S J Allinson, David Williamson, Robin J Borchert, Saber Sami, Thomas E Cope, W Richard Bevan-Jones, P Simon Jones, Robert Arnold, Ajenthan Surendranathan, Elijah Mak, Li Su, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Row. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122879. |
the ability to assess the distribution and extent of tau pathology in alzheimer's disease and progressive supranuclear palsy in vivo would help to develop biomarkers for these tauopathies and clinical trials of disease-modifying therapies. |
2017-05-29 |
2023-08-13 |
human |
| Luca Passamonti, Patricia Vázquez Rodríguez, Young T Hong, Kieren S J Allinson, David Williamson, Robin J Borchert, Saber Sami, Thomas E Cope, W Richard Bevan-Jones, P Simon Jones, Robert Arnold, Ajenthan Surendranathan, Elijah Mak, Li Su, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Row. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122879. |
we assessed the radiotracer 18f-av-1451 with positron emission tomography imaging to compare the distribution and intensity of tau pathology in 15 patients with alzheimer's pathology (including amyloid-positive mild cognitive impairment), 19 patients with progressive supranuclear palsy, and 13 age- and sex-matched controls. |
2017-05-29 |
2023-08-13 |
human |
| Luca Passamonti, Patricia Vázquez Rodríguez, Young T Hong, Kieren S J Allinson, David Williamson, Robin J Borchert, Saber Sami, Thomas E Cope, W Richard Bevan-Jones, P Simon Jones, Robert Arnold, Ajenthan Surendranathan, Elijah Mak, Li Su, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Row. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122879. |
we also examined the 18f-av-1451 autoradiographic binding in post-mortem tissue from patients with alzheimer's disease, progressive supranuclear palsy, and a control case to assess the 18f-av-1451 binding specificity to alzheimer's and non-alzheimer's tau pathology. |
2017-05-29 |
2023-08-13 |
human |
| Luca Passamonti, Patricia Vázquez Rodríguez, Young T Hong, Kieren S J Allinson, David Williamson, Robin J Borchert, Saber Sami, Thomas E Cope, W Richard Bevan-Jones, P Simon Jones, Robert Arnold, Ajenthan Surendranathan, Elijah Mak, Li Su, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Row. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain : a journal of neurology. vol 140. issue 3. 2017-05-29. PMID:28122879. |
we suggest that 18f-av-1451 positron emission tomography is a useful biomarker to assess tau pathology in alzheimer's disease and to distinguish it from other tauopathies with distinct clinical and pathological characteristics such as progressive supranuclear palsy. |
2017-05-29 |
2023-08-13 |
human |
| Chiara Giacomelli, Simona Daniele, Claudia Martin. Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. Biochemical pharmacology. vol 131. 2017-05-29. PMID:28159621. |
β-amyloid (aβ) peptide-containing plaques and intraneuronal neurofibrillary tangles composed of hyperphosphorylated protein tau are the two main neuropathological lesions in alzheimer's disease. |
2017-05-29 |
2023-08-13 |
Not clear |